In a recent corporate announcement, AIM VACCINE (06660) has confirmed the formal approval of several key appointments by its shareholders.

Resolutions to appoint Ms. Liu Ling as an executive director of the company, and to appoint Mr. Ouyang Hui and Mr. Shao Weicai as independent non-executive directors, were duly passed at the Annual General Meeting. These appointments became effective immediately upon the conclusion of the meeting.

Following amendments to the company's articles of association and the appointment of the new independent directors, the resignation of Ms. Wen Jie from her roles as independent non-executive director, member of the audit committee, member of the remuneration and assessment committee, and member of the nomination committee took effect from June 10, 2026.

Concurrently, Mr. Wu Jinian has been appointed as the company's Executive President, Chief Scientist, and Director of the R&D Management Committee. He will be responsible for overseeing the company's research, development, and related activities.

Mr. Wu's term commenced on June 10, 2026, and will conclude upon the expiry of the second term of the board of directors.